Liquid biopsy has emerged as a powerful, noninvasive tool for the detection and monitoring of cancer. It relies on identifying tumor markers, such as circulating tumor cells (CTCs), cell-free tumor DNA (ctDNA), cell-free RNA (cfRNA), exosomes, as well as tumor-derived metabolites and proteins in biofluids.
1 Prior studies in individuals with renal cell carcinoma (RCC) have reported negative correlations between ctDNA levels and clinical outcomes, including cancer-specific survival,
2 progression-free survival (PFS),
2,3 and overall survival (OS).
3 In this issue of
The Oncologist, Correa et al build upon these foundations using a bespoke whole-exome sequencing (WES)-informed ctDNA assay (Signatera RUO, Natera, Inc.), demonstrating its prognostic value for RCC recurrence in patients who underwent nephrectomy.
4 The authors conducted deep WES on formalin-fixed, paraffin-embedded (FFPE) tumor samples and matched normal blood samples from 45 patients to identify somatic single nucleotide variants present in the tumor but not in germline DNA. By assaying cell-free DNA for these patient-specific, bespoke panel of mutations, the authors detected ctDNA in 18 of 36 (50%) patients tested preoperatively and in 12 of 45 (27%) after nephrectomy. Preoperative ctDNA detection was not correlated with disease grade but was associated with a larger primary tumor. The authors showed that the pre- and post-operative detection of ctDNA was significantly associated with a shorter recurrence-free survival (hazard ratio (HR) 2.7,
P = 0.046 and HR 3.23,
P = 0.003, respectively). These findings represent a step toward guiding the use of adjuvant therapies in patients who are at high risk of relapse or not cured by nephrectomy based on ctDNA levels. However, despite employing a bespoke approach optimized for sensitivity, the ability to detect ctDNA was limited. Only 27% (12 of 45) of patients had ctDNA detected at any time after surgery in a population that ended up with a 60% rate (27 of 45) of established recurrences. A warranted question thus emerges: could emerging liquid biopsy technologies improve sensitivity by looking beyond somatic mutations?